title: [The analysis of failures in the treatment of children with non-B non-Hodgkin's lymphoma. Polish pediatric leukemia/lymphoma study group report].
abstract: The aim of the study was to evaluate the results of treatment of 46 children with non B non-Hodgkin's Lymphoma registered in 7 centers of Polish Paediatric Leukaemia/Lymphoma Study Group from 1993 to 1998. The patients were treated according to BFM-90 protocol based on German regimen. The overall probability of event-free survival for the all children after 4 years of follow-up was 71%, for patients in stage III--65%, stage IV--70%. The achieved results were not as positive as in the BFM Study Group, what was related to: the great number of children with advanced stage of disease (54.3%), the late final diagnosis, the great number of recurrences (22.5%) and deaths caused by the toxicity of medication (6.5%) (infections, drug toxicity).
authors.affiliation: Kliniki Hematologii i Chorób Rozrostowych Dzieci Akademii Medycznej we Wrocławiu.
authors.forename: G
authors.initials: G
authors.lastname: Wróbel
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: B
authors.initials: B
authors.lastname: Kazanowska
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: H
authors.initials: H
authors.lastname: Bubała
authors.forename: A
authors.initials: A
authors.lastname: Dłuzniewska
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: B
authors.initials: B
authors.lastname: Sopyło
authors.forename: M J
authors.initials: MJ
authors.lastname: Stefaniak
authors.forename: K
authors.initials: K
authors.lastname: Stefańska
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: E
authors.initials: E
authors.lastname: Stańczak
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging; D011044:Poland; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate; D017211:Treatment Failure; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin